Clinical Influence of Anastomotic Leakage on Esophageal Cancer Survival and Recurrence.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 15 11 2019
revised: 26 11 2019
accepted: 02 12 2019
entrez: 2 1 2020
pubmed: 2 1 2020
medline: 10 1 2020
Statut: ppublish

Résumé

We investigated the clinical influence of anastomotic leak (AL) on esophageal cancer survival and recurrence after curative surgery. This study included 122 patients who underwent curative surgery for esophageal cancer between 2008 and 2018. The patients were classified into those with AL and those without. The risk factors for overall (OS) and recurrence-free (RFS) survival were identified. AL was found in 44 out of the 122 patients (36.1%). The respective OS rates at 3 and 5 years after surgery were 43.9% and 40.2% in the AL group and 63.9% and 53.2% in the non-AL group, which were significantly different (p=0.0049). In contrast, the respective RFS rates at 3 and 5 years after surgery were 44.8% and 29.8%, and 44.9% and 42.4%, which were not significantly different (p=0.2306). A multivariate analysis showed that AL was a significant independent risk factor for both poorer OS and RFS in patients who underwent curative surgery for esophageal cancer. To improve survival of patients with esophageal cancer, the surgical procedure, perioperative care and surgical strategy must be carefully planned in order to prevent AL.

Sections du résumé

BACKGROUND BACKGROUND
We investigated the clinical influence of anastomotic leak (AL) on esophageal cancer survival and recurrence after curative surgery.
PATIENTS AND METHODS METHODS
This study included 122 patients who underwent curative surgery for esophageal cancer between 2008 and 2018. The patients were classified into those with AL and those without. The risk factors for overall (OS) and recurrence-free (RFS) survival were identified.
RESULTS RESULTS
AL was found in 44 out of the 122 patients (36.1%). The respective OS rates at 3 and 5 years after surgery were 43.9% and 40.2% in the AL group and 63.9% and 53.2% in the non-AL group, which were significantly different (p=0.0049). In contrast, the respective RFS rates at 3 and 5 years after surgery were 44.8% and 29.8%, and 44.9% and 42.4%, which were not significantly different (p=0.2306). A multivariate analysis showed that AL was a significant independent risk factor for both poorer OS and RFS in patients who underwent curative surgery for esophageal cancer.
CONCLUSION CONCLUSIONS
To improve survival of patients with esophageal cancer, the surgical procedure, perioperative care and surgical strategy must be carefully planned in order to prevent AL.

Identifiants

pubmed: 31892599
pii: 40/1/443
doi: 10.21873/anticanres.13972
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

443-449

Informations de copyright

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Toru Aoyama (T)

Department of Surgery, Yokohama City University, Yokohama, Japan t-aoyama@lilac.plala.or.jp.

Keisuke Kazama (K)

Department of Surgery, Yokohama City University, Yokohama, Japan.

Yosuke Atsumi (Y)

Department of Surgery, Yokohama City University, Yokohama, Japan.

Hiroshi Tamagawa (H)

Department of Surgery, Yokohama City University, Yokohama, Japan.

Ayaka Tamagawa (A)

Department of Surgery, Yokohama City University, Yokohama, Japan.

Keisuke Komori (K)

Department of Surgery, Yokohama City University, Yokohama, Japan.

Daisuke Machida (D)

Department of Surgery, Yokohama City University, Yokohama, Japan.

Yukio Maezawa (Y)

Department of Surgery, Yokohama City University, Yokohama, Japan.

Kazuki Kano (K)

Department of Surgery, Yokohama City University, Yokohama, Japan.

Kentaro Hara (K)

Department of Surgery, Yokohama City University, Yokohama, Japan.

Masaaki Murakawa (M)

Department of Surgery, Yokohama City University, Yokohama, Japan.

Masakatsu Numata (M)

Department of Surgery, Yokohama City University, Yokohama, Japan.

Takashi Oshima (T)

Department of Surgery, Yokohama City University, Yokohama, Japan.

Norio Yukawa (N)

Department of Surgery, Yokohama City University, Yokohama, Japan.

Munetaka Masuda (M)

Department of Surgery, Yokohama City University, Yokohama, Japan.

Yasushi Rino (Y)

Department of Surgery, Yokohama City University, Yokohama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH